Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma

A nationwide survey in Japan

Sung Won Kim, Tetsuya E. Tanimoto, Noriyuki Hirabayashi, Seiichi Goto, Masahiro Kami, Satoshi Yoshioka, Toshiki Uchida, Kenji Kishi, Yuji Tanaka, Akio Kohno, Masaharu Kasai, Masakazu Higuchi, Masanobu Kasai, Shin Ichiro Mori, Takahiro Fukuda, Koji Izutsu, Hiroshi Sao, Takayuki Ishikawa, Tatsuo Ichinohe, Kengo Takeuchi & 7 others Kinuko Tajima, Ryuji Tanosaki, Mine Harada, Shuichi Taniguchi, Kensei Tobinai, Tomomitsu Hotta, Yoichi Takaue

Research output: Contribution to journalReview article

62 Citations (Scopus)

Abstract

We retrospectively surveyed the data of 233 patients who underwent myeloablative allogeneic hematopoietic stem cell transplantation (allo-HSCT) for non-Hodgkin lymphoma (NHL). Donors were HLA-matched relatives in 154 patients (66%) or unrelated volunteers in 60 (26%). Ninety patients (39%) were in complete remission. One hundred ninety-three (83%) received a total body irradiation (TBI)-based regimen, and 40 (17%) received a non-TBI-based regimen. Acute graft-versus-host disease (GVHD) occurred in 155 (67%) of the 233 evaluable patients; grade II to IV in 90 (39%), and grade III to IV in 37 (16%). Treatment-related mortality (TRM) was observed in 98 patients (42%), and 68% of them were related to GVHD. In a multivariate analysis, chemoresistance, prior autograft, and chronic GVHD were identified as adverse prognostic factors for TRM. Relapse or progression of lymphoma was observed in 21%. The 2-year overall survival rates of the patients with indolent (n = 38), aggressive (n = 111), and lymphoblastic lymphoma (n = 84) were 57%, 42%, and 41%, respectively. In a multivariate analysis, chemoresistance, prior autograft, and prior radiotherapy were identified as adverse prognostic factors for overall survival. Although myeloablative allo-HSCT represents an effective therapeutic option for patients with NHL, more work is still needed to decrease TRM and relapse.

Original languageEnglish
Pages (from-to)382-389
Number of pages8
JournalBlood
Volume108
Issue number1
DOIs
Publication statusPublished - 2006 Jul 1
Externally publishedYes

Fingerprint

Hematopoietic Stem Cell Transplantation
Stem cells
Grafts
Non-Hodgkin's Lymphoma
Japan
Autografts
Irradiation
Graft vs Host Disease
Radiotherapy
Mortality
Multivariate Analysis
Recurrence
Whole-Body Irradiation
Therapeutics
Surveys and Questionnaires
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Volunteers
Lymphoma
Survival Rate
Tissue Donors

ASJC Scopus subject areas

  • Hematology

Cite this

Kim, S. W., Tanimoto, T. E., Hirabayashi, N., Goto, S., Kami, M., Yoshioka, S., ... Takaue, Y. (2006). Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: A nationwide survey in Japan. Blood, 108(1), 382-389. https://doi.org/10.1182/blood-2005-02-0596

Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma : A nationwide survey in Japan. / Kim, Sung Won; Tanimoto, Tetsuya E.; Hirabayashi, Noriyuki; Goto, Seiichi; Kami, Masahiro; Yoshioka, Satoshi; Uchida, Toshiki; Kishi, Kenji; Tanaka, Yuji; Kohno, Akio; Kasai, Masaharu; Higuchi, Masakazu; Kasai, Masanobu; Mori, Shin Ichiro; Fukuda, Takahiro; Izutsu, Koji; Sao, Hiroshi; Ishikawa, Takayuki; Ichinohe, Tatsuo; Takeuchi, Kengo; Tajima, Kinuko; Tanosaki, Ryuji; Harada, Mine; Taniguchi, Shuichi; Tobinai, Kensei; Hotta, Tomomitsu; Takaue, Yoichi.

In: Blood, Vol. 108, No. 1, 01.07.2006, p. 382-389.

Research output: Contribution to journalReview article

Kim, SW, Tanimoto, TE, Hirabayashi, N, Goto, S, Kami, M, Yoshioka, S, Uchida, T, Kishi, K, Tanaka, Y, Kohno, A, Kasai, M, Higuchi, M, Kasai, M, Mori, SI, Fukuda, T, Izutsu, K, Sao, H, Ishikawa, T, Ichinohe, T, Takeuchi, K, Tajima, K, Tanosaki, R, Harada, M, Taniguchi, S, Tobinai, K, Hotta, T & Takaue, Y 2006, 'Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: A nationwide survey in Japan', Blood, vol. 108, no. 1, pp. 382-389. https://doi.org/10.1182/blood-2005-02-0596
Kim, Sung Won ; Tanimoto, Tetsuya E. ; Hirabayashi, Noriyuki ; Goto, Seiichi ; Kami, Masahiro ; Yoshioka, Satoshi ; Uchida, Toshiki ; Kishi, Kenji ; Tanaka, Yuji ; Kohno, Akio ; Kasai, Masaharu ; Higuchi, Masakazu ; Kasai, Masanobu ; Mori, Shin Ichiro ; Fukuda, Takahiro ; Izutsu, Koji ; Sao, Hiroshi ; Ishikawa, Takayuki ; Ichinohe, Tatsuo ; Takeuchi, Kengo ; Tajima, Kinuko ; Tanosaki, Ryuji ; Harada, Mine ; Taniguchi, Shuichi ; Tobinai, Kensei ; Hotta, Tomomitsu ; Takaue, Yoichi. / Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma : A nationwide survey in Japan. In: Blood. 2006 ; Vol. 108, No. 1. pp. 382-389.
@article{5b7fa9878568495ea0c8ff47662edb44,
title = "Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: A nationwide survey in Japan",
abstract = "We retrospectively surveyed the data of 233 patients who underwent myeloablative allogeneic hematopoietic stem cell transplantation (allo-HSCT) for non-Hodgkin lymphoma (NHL). Donors were HLA-matched relatives in 154 patients (66{\%}) or unrelated volunteers in 60 (26{\%}). Ninety patients (39{\%}) were in complete remission. One hundred ninety-three (83{\%}) received a total body irradiation (TBI)-based regimen, and 40 (17{\%}) received a non-TBI-based regimen. Acute graft-versus-host disease (GVHD) occurred in 155 (67{\%}) of the 233 evaluable patients; grade II to IV in 90 (39{\%}), and grade III to IV in 37 (16{\%}). Treatment-related mortality (TRM) was observed in 98 patients (42{\%}), and 68{\%} of them were related to GVHD. In a multivariate analysis, chemoresistance, prior autograft, and chronic GVHD were identified as adverse prognostic factors for TRM. Relapse or progression of lymphoma was observed in 21{\%}. The 2-year overall survival rates of the patients with indolent (n = 38), aggressive (n = 111), and lymphoblastic lymphoma (n = 84) were 57{\%}, 42{\%}, and 41{\%}, respectively. In a multivariate analysis, chemoresistance, prior autograft, and prior radiotherapy were identified as adverse prognostic factors for overall survival. Although myeloablative allo-HSCT represents an effective therapeutic option for patients with NHL, more work is still needed to decrease TRM and relapse.",
author = "Kim, {Sung Won} and Tanimoto, {Tetsuya E.} and Noriyuki Hirabayashi and Seiichi Goto and Masahiro Kami and Satoshi Yoshioka and Toshiki Uchida and Kenji Kishi and Yuji Tanaka and Akio Kohno and Masaharu Kasai and Masakazu Higuchi and Masanobu Kasai and Mori, {Shin Ichiro} and Takahiro Fukuda and Koji Izutsu and Hiroshi Sao and Takayuki Ishikawa and Tatsuo Ichinohe and Kengo Takeuchi and Kinuko Tajima and Ryuji Tanosaki and Mine Harada and Shuichi Taniguchi and Kensei Tobinai and Tomomitsu Hotta and Yoichi Takaue",
year = "2006",
month = "7",
day = "1",
doi = "10.1182/blood-2005-02-0596",
language = "English",
volume = "108",
pages = "382--389",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma

T2 - A nationwide survey in Japan

AU - Kim, Sung Won

AU - Tanimoto, Tetsuya E.

AU - Hirabayashi, Noriyuki

AU - Goto, Seiichi

AU - Kami, Masahiro

AU - Yoshioka, Satoshi

AU - Uchida, Toshiki

AU - Kishi, Kenji

AU - Tanaka, Yuji

AU - Kohno, Akio

AU - Kasai, Masaharu

AU - Higuchi, Masakazu

AU - Kasai, Masanobu

AU - Mori, Shin Ichiro

AU - Fukuda, Takahiro

AU - Izutsu, Koji

AU - Sao, Hiroshi

AU - Ishikawa, Takayuki

AU - Ichinohe, Tatsuo

AU - Takeuchi, Kengo

AU - Tajima, Kinuko

AU - Tanosaki, Ryuji

AU - Harada, Mine

AU - Taniguchi, Shuichi

AU - Tobinai, Kensei

AU - Hotta, Tomomitsu

AU - Takaue, Yoichi

PY - 2006/7/1

Y1 - 2006/7/1

N2 - We retrospectively surveyed the data of 233 patients who underwent myeloablative allogeneic hematopoietic stem cell transplantation (allo-HSCT) for non-Hodgkin lymphoma (NHL). Donors were HLA-matched relatives in 154 patients (66%) or unrelated volunteers in 60 (26%). Ninety patients (39%) were in complete remission. One hundred ninety-three (83%) received a total body irradiation (TBI)-based regimen, and 40 (17%) received a non-TBI-based regimen. Acute graft-versus-host disease (GVHD) occurred in 155 (67%) of the 233 evaluable patients; grade II to IV in 90 (39%), and grade III to IV in 37 (16%). Treatment-related mortality (TRM) was observed in 98 patients (42%), and 68% of them were related to GVHD. In a multivariate analysis, chemoresistance, prior autograft, and chronic GVHD were identified as adverse prognostic factors for TRM. Relapse or progression of lymphoma was observed in 21%. The 2-year overall survival rates of the patients with indolent (n = 38), aggressive (n = 111), and lymphoblastic lymphoma (n = 84) were 57%, 42%, and 41%, respectively. In a multivariate analysis, chemoresistance, prior autograft, and prior radiotherapy were identified as adverse prognostic factors for overall survival. Although myeloablative allo-HSCT represents an effective therapeutic option for patients with NHL, more work is still needed to decrease TRM and relapse.

AB - We retrospectively surveyed the data of 233 patients who underwent myeloablative allogeneic hematopoietic stem cell transplantation (allo-HSCT) for non-Hodgkin lymphoma (NHL). Donors were HLA-matched relatives in 154 patients (66%) or unrelated volunteers in 60 (26%). Ninety patients (39%) were in complete remission. One hundred ninety-three (83%) received a total body irradiation (TBI)-based regimen, and 40 (17%) received a non-TBI-based regimen. Acute graft-versus-host disease (GVHD) occurred in 155 (67%) of the 233 evaluable patients; grade II to IV in 90 (39%), and grade III to IV in 37 (16%). Treatment-related mortality (TRM) was observed in 98 patients (42%), and 68% of them were related to GVHD. In a multivariate analysis, chemoresistance, prior autograft, and chronic GVHD were identified as adverse prognostic factors for TRM. Relapse or progression of lymphoma was observed in 21%. The 2-year overall survival rates of the patients with indolent (n = 38), aggressive (n = 111), and lymphoblastic lymphoma (n = 84) were 57%, 42%, and 41%, respectively. In a multivariate analysis, chemoresistance, prior autograft, and prior radiotherapy were identified as adverse prognostic factors for overall survival. Although myeloablative allo-HSCT represents an effective therapeutic option for patients with NHL, more work is still needed to decrease TRM and relapse.

UR - http://www.scopus.com/inward/record.url?scp=33745627072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745627072&partnerID=8YFLogxK

U2 - 10.1182/blood-2005-02-0596

DO - 10.1182/blood-2005-02-0596

M3 - Review article

VL - 108

SP - 382

EP - 389

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -